COMPANY

Sarepta Therapeutics, Inc.

HQ: Cambridge, MA source · sarepta.com ↗ · New England

FDA-approved therapeutic company Clinical Phase 3

21 open jobs · last seen Oct 23, 2026 · 52 sources

To correct this mis-regulation, Sarepta is investigating an RNAi conjugate designed to target and suppress DMPK in skeletal muscle. From company website Source · Oct 13, 2026

Keywords: rnai Duchenne Muscular Dystrophy Limb-girdle Muscular Dystrophy Marburg Hemorrhagic Fever Ebola Hemorrhagic Fever Myotonic Dystrophy 1 Facioscapulohumeral Muscular Dystrophy Huntington's Disease Type 2E Limb-Girdle Muscular Dystrophy Limb Girdle Muscular Dystrophy Type 2D/R3 Limb-Girdle Muscular Dystrophies Type 2D Limb-Girdle Muscular Dystrophy Dysferlinopathy Influenza West Nile Fever Encephalitis Cardiovascular Disease Coronary Artery Bypass West Nile Virus Hepatitis C delandistrogene moxeparvovec SRP-9003 Eteplirsen SRP-4045 SRP-4053 SRP-9004 SRP-5051 AVI-4658 (Eteplirsen) AVI-4020 AVI-4065 SRP-1003 SRP-1001 SRP-1005 SRP-6004 SRP-9005 Vesleteplirsen rAAVrh74.MHCK7.DYSF.DV AVI-4658 AVI-7288

Profile checked Oct 10, 2026

21Open jobs 52Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Director, Biostatistics	2 locations (listed on the posting)	Oct 21, 2026	Oct 9, 2026
Associate Director, Medical Writing	14 locations (listed on the posting)	Oct 20, 2026	Oct 20, 2026
Director, Global Pharmacovigilance Operations Lead	Cambridge, MA	Oct 20, 2026	Oct 20, 2026
Research Associate I	Columbus, OH	Oct 20, 2026	Oct 20, 2026
Senior Director, National Accounts (California)	San Francisco, CA	Oct 13, 2026	Oct 9, 2026

See all 21 jobs

Timeline

Oct 30, 2026 Trial start Phase 4: Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting source ↗
Oct 9, 2026 Board tracked Radar started tracking this company’s job board (21 open jobs at last check). source ↗
May 12, 2026 Trial start Phase 1: A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease source ↗
Dec 11, 2025 Debt Debt: $291M (not counted as a raise), announced Dec 11, 2025. Source: SEC filing. source ↗
Jun 30, 2025 Trial start Phase 3: A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants source ↗
Jan 9, 2025 Trial start Phase 1: Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States source ↗
Sep 18, 2024 Trial start Phase 1: A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Mus source ↗
Jun 19, 2024 Trial start Phase 1/Phase 2: Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 source ↗
Mar 4, 2024 Trial start Phase 1/Phase 2: Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy source ↗
Feb 7, 2024 Trial start —: An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy source ↗
Jan 29, 2024 Trial start Phase 1: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DM source ↗
Jan 15, 2024 Trial start Phase 3: A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 source ↗
Sep 27, 2023 Trial start Phase 3: A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study source ↗
May 31, 2023 Trial start Phase 3: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DM source ↗
May 22, 2023 Trial start Phase 1: A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Rel source ↗
Dec 19, 2022 Trial start Phase 1: A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 ( source ↗
Oct 27, 2021 Trial start Phase 3: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) source ↗
Apr 22, 2021 Trial start —: A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice source ↗
Nov 23, 2020 Trial start Phase 1: A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Coh source ↗
Jul 13, 2020 Trial start Phase 3: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) source ↗
Jun 26, 2019 Trial start Phase 2: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatme source ↗
Jun 26, 2019 Trial start Phase 2: A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995) source ↗
Jan 7, 2019 Trial start —: A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice source ↗
Dec 19, 2018 Trial start Phase 1/Phase 2: An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen) source ↗
Dec 5, 2018 Trial start Phase 1/Phase 2: A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD) source ↗

Showing 25 of 52 dated events.

Upcoming milestones

Oct 31, 2026 (ESTIMATED) · Phase 3 · A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) · NCT03992430
Dec 31, 2026 (ESTIMATED) · Phase 1/Phase 2 · Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy · NCT06138743
May 31, 2027 (ESTIMATED) · Phase 3 · A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) · NCT05881408
Aug 31, 2027 (ESTIMATED) · Phase 4 · Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting · NCT07542314
Nov 30, 2027 (ESTIMATED) · Phase 1 · A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease · NCT07536061
Dec 31, 2027 (ESTIMATED) · Phase 1 · A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort · NCT04626674
Aug 28, 2028 (ESTIMATED) · Phase 1 · A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarc · NCT05876780
Dec 31, 2028 (ESTIMATED) · Phase 1/Phase 2 · Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 · NCT06131983

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 21

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Director, Biostatistics	2 locations (listed on the posting)	Oct 21, 2026	Oct 9, 2026	Senior
Associate Director, Medical Writing	14 locations (listed on the posting)	Oct 20, 2026	Oct 20, 2026	Not stated
Director, Global Pharmacovigilance Operations Lead	Cambridge, MA	Oct 20, 2026	Oct 20, 2026	Not stated
Research Associate I	Columbus, OH	Oct 20, 2026	Oct 20, 2026	Not stated
Senior Director, National Accounts (California)	San Francisco, CA	Oct 13, 2026	Oct 9, 2026	Senior
Director, Digital Marketing & Strategy	Cambridge, MA	Oct 12, 2026	Oct 12, 2026	Senior
Director, Translational Operations and Regulatory Integration	Columbus, OH	Oct 12, 2026	Oct 12, 2026	Senior
Director, Medical Managed Care	4 locations (listed on the posting)	Oct 9, 2026	Oct 9, 2026	Senior
Senior Neuromuscular Clinical Sales Specialist - Mountain West	4 locations (listed on the posting)	Oct 7, 2026	Oct 9, 2026	Senior
Associate Director, Regulatory Labeling and Disclosures	15 locations (listed on the posting)	Oct 6, 2026	Oct 9, 2026	Senior
Executive Medical Director, SERM	Cambridge, MA	Oct 5, 2026	Oct 9, 2026	Executive
Associate Director, GRA	Cambridge, MA	Sep 28, 2026	Oct 9, 2026	Senior
Director, Medical Engagement Lead	3 locations (listed on the posting)	Sep 28, 2026	Oct 9, 2026	Senior
Director, Scientific Technology & Laboratory Systems	Cambridge, MA	Sep 26, 2026	Oct 9, 2026	Senior
Director, Corporate Quality - GCP	2 locations (listed on the posting)	Sep 23, 2026	Oct 9, 2026	Senior
Director, Commercial Learning and Development	Cambridge, MA	Sep 23, 2026	Oct 9, 2026	Senior
Medical Science Liaison	Midwest (Field)	Sep 23, 2026	Oct 9, 2026	Mid
Director, Patient Advocacy	Cambridge, MA	Sep 23, 2026	Oct 9, 2026	Senior
Senior Manager, Corporate Quality – R&D Audits	Bedford, MA	Sep 23, 2026	Oct 9, 2026	Senior
Director, Patient Focused Drug Development and Innovation	Cambridge, MA	Sep 23, 2026	Oct 9, 2026	Senior
Senior Neuromuscular Clinical Sales Specialist - Northeast	8 locations (listed on the posting)	Sep 22, 2026	Oct 9, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Debt: $291.0M. Last 2 years.

Dec 11, 2025 Debt: $291M (not counted as a raise), announced Dec 11, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) Showing 50 of 52

Record	Title	Phase	Status	Start	Primary completion
NCT07542314	Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting	Phase 4	Recruiting	Oct 30, 2026	Aug 31, 2027 (estimated)
NCT06138743	Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy	Phase 1/Phase 2	Enrolling by invitation	Mar 4, 2024	Dec 31, 2026 (estimated)
NCT06131983	Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1	Phase 1/Phase 2	Enrolling by invitation	Jun 19, 2024	Dec 31, 2028 (estimated)
NCT04626674	A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort	Phase 1	Recruiting	Nov 23, 2020	Dec 31, 2027 (estimated)
NCT07536061	A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease	Phase 1	Recruiting	May 12, 2026	Nov 30, 2027 (estimated)
NCT05881408	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)	Phase 3	Active, not recruiting	May 31, 2023	May 31, 2027 (estimated)
NCT06270719	An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy	Not listed	Enrolling by invitation	Feb 7, 2024	Dec 31, 2029 (estimated)
NCT06246513	A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4	Phase 3	Active, not recruiting	Jan 15, 2024	Mar 4, 2025 (actual)
NCT03992430	A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)	Phase 3	Active, not recruiting	Jul 13, 2020	Oct 31, 2026 (estimated)
NCT05876780	A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)	Phase 1	Active, not recruiting	Dec 19, 2022	Aug 28, 2028 (estimated)
NCT05967351	A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study	Phase 3	Enrolling by invitation	Sep 27, 2023	Oct 31, 2033 (estimated)
NCT03652259	Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)	Phase 1/Phase 2	Terminated	Oct 27, 2018	Jan 14, 2025 (actual)
NCT06241950	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)	Phase 1	Terminated	Jan 29, 2024	Oct 10, 2025 (actual)
NCT02500381	Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)	Phase 3	Completed	Sep 28, 2016	Nov 12, 2024 (actual)
NCT04475926	A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice	Not listed	Active, not recruiting	Apr 22, 2021	Sep 5, 2030 (estimated)
NCT06606340	A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice	Not listed	Enrolling by invitation	Jan 7, 2019	Dec 31, 2033 (estimated)
NCT05906251	A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)	Phase 1	Terminated	May 22, 2023	Jun 13, 2025 (actual)
NCT06747273	Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States	Phase 1	Terminated	Jan 9, 2025	Jun 18, 2025 (actual)
NCT06597656	A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74	Phase 1	Terminated	Sep 18, 2024	Aug 5, 2025 (actual)
NCT06952686	A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants	Phase 3	Withdrawn	Jun 30, 2025	Nov 30, 2030 (estimated)
NCT05096221	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)	Phase 3	Completed	Oct 27, 2021	Oct 4, 2023 (actual)
NCT04004065	Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment	Phase 2	Terminated	Jun 26, 2019	Oct 30, 2023 (actual)
NCT03769116	A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)	Phase 1/Phase 2	Completed	Dec 5, 2018	Dec 8, 2020 (actual)
NCT03375164	A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)	Phase 1/Phase 2	Completed	Jan 4, 2018	Apr 25, 2023 (actual)
NCT03675126	An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)	Phase 1/Phase 2	Terminated	Dec 19, 2018	Aug 25, 2021 (actual)
NCT03532542	An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy	Phase 3	Terminated	Aug 2, 2018	Jul 26, 2023 (actual)
NCT03985878	A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)	Phase 2	Terminated	Jun 26, 2019	Aug 31, 2022 (actual)
NCT01976091	A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)	Phase 1/Phase 2	Completed	Feb 1, 2015	Mar 14, 2019 (actual)
NCT03375255	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)	Phase 1	Completed	Feb 5, 2018	Aug 19, 2019 (actual)
NCT03218995	Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping	Phase 2	Completed	Aug 16, 2017	Mar 10, 2021 (actual)
NCT02530905	Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients	Phase 1	Completed	Oct 8, 2015	Oct 3, 2018 (actual)
NCT02710500	rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies	Phase 1	Completed	2016-03	2019-07 (actual)
NCT02255552	Study of Eteplirsen in DMD Patients	Phase 3	Completed	Nov 17, 2014	Jun 14, 2019 (actual)
NCT02420379	Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy	Phase 2	Completed	Jun 30, 2015	Dec 17, 2018 (actual)
NCT02310906	Phase I/II Study of SRP-4053 in DMD Patients	I	Completed	Jan 13, 2015	Mar 25, 2019 (actual)
NCT01540409	Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy	Phase 2	Completed	Feb 27, 2012	Apr 15, 2016 (actual)
NCT01396239	Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients	Phase 2	Completed	2011-07	2012-02 (actual)
NCT02286947	Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy	Phase 2	Completed	2014-11	Apr 21, 2017 (actual)
NCT00844597	Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients	Phase 1/Phase 2	Completed	2009-01	2010-06 (actual)
NCT01566877	A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers	Phase 1	Completed	2013-05	2014-01 (actual)
NCT01375985	Safety Study of Single Administration Intravenous Treatment for Influenza	Phase 1	Terminated	2011-06	2011-08 (actual)
NCT01593072	A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers	Phase 1	Withdrawn	2012-08	2013-01 (estimated)
NCT01353040	Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus	Phase 1	Completed	2011-05	2011-12 (actual)
NCT01353027	Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus	Phase 1	Completed	2010-05	2011-11 (actual)
NCT00343148	Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid	Phase 1	Completed	2006-06	2006-06 (actual)
NCT00091845	An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease	Phase 1	Terminated	2004-11	Not listed
NCT00381433	Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid	Phase 1	Completed	2006-09	2006-10 (actual)
NCT00451256	Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)	Phase 2	Terminated	2007-03	2007-11 (actual)
NCT00387283	Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020	Phase 1	Completed	2006-10	2006-12 (actual)
NCT00229749	Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients	Phase 1/Phase 2	Terminated	2005-09	2006-10 (actual)

Connect

Contact page